Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Indaptus Therapeutics ( (INDP) ) just unveiled an announcement.
Indaptus Therapeutics completed a private placement of convertible promissory notes and warrants, raising approximately $5.7 million in June 2025. The notes were converted into common stock, and additional warrants were issued to investors and placement agents. A special shareholder meeting on July 25, 2025, approved proposals related to this placement, ensuring compliance with Nasdaq listing rules.
The most recent analyst rating on (INDP) stock is a Buy with a $224.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.
Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic products. The company primarily engages in the research and development of treatments for diseases with significant unmet medical needs.
Average Trading Volume: 242,333
Technical Sentiment Signal: Sell
Current Market Cap: $5.92M
For detailed information about INDP stock, go to TipRanks’ Stock Analysis page.